Cargando…
Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution
PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions f...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697451/ https://www.ncbi.nlm.nih.gov/pubmed/29180903 http://dx.doi.org/10.2147/CLEP.S148671 |
_version_ | 1783280624832872448 |
---|---|
author | Laugesen, Kristina Støvring, Henrik Hallas, Jesper Pottegård, Anton Jørgensen, Jens Otto Lunde Sørensen, Henrik Toft Petersen, Irene |
author_facet | Laugesen, Kristina Støvring, Henrik Hallas, Jesper Pottegård, Anton Jørgensen, Jens Otto Lunde Sørensen, Henrik Toft Petersen, Irene |
author_sort | Laugesen, Kristina |
collection | PubMed |
description | PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions for oral glucocorticoids and to describe continuous treatment episodes using the parametric waiting time distribution. METHODS: We used Danish nationwide registries to identify all prescriptions for oral glucocorticoids during 1996–2014. We applied the parametric waiting time distribution to estimate duration of individual prescriptions each year by estimating the 80th, 90th, 95th and 99th percentiles for the interarrival distribution. These corresponded to the time since last prescription during which 80%, 90%, 95% and 99% of users presented a new prescription for redemption. We used the Kaplan–Meier survival function to estimate length of first continuous treatment episodes by assigning estimated prescription duration to each prescription and thereby create treatment episodes from overlapping prescriptions. RESULTS: We identified 5,691,985 prescriptions issued to 854,429 individuals of whom 351,202 (41%) only redeemed 1 prescription in the whole study period. The 80th percentile for prescription duration ranged from 87 to 120 days, the 90th percentile from 116 to 150 days, the 95th percentile from 147 to 181 days, and the 99th percentile from 228 to 259 days during 1996–2014. Based on the 80th, 90th, 95th and 99th percentiles of prescription duration, the median length of continuous treatment was 113, 141, 170 and 243 days, respectively. CONCLUSION: Our method and results may provide an important framework for future pharmacoepidemiological studies. The choice of which percentile of the interarrival distribution to apply as prescription duration has an impact on the level of misclassification. Use of the 80th percentile provides a measure of drug exposure that is specific, while the 99th percentile provides a sensitive measure. |
format | Online Article Text |
id | pubmed-5697451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-56974512017-11-27 Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution Laugesen, Kristina Støvring, Henrik Hallas, Jesper Pottegård, Anton Jørgensen, Jens Otto Lunde Sørensen, Henrik Toft Petersen, Irene Clin Epidemiol Original Research PURPOSE: Glucocorticoids are widely used medications. In many pharmacoepidemiological studies, duration of individual prescriptions and definition of treatment episodes are important issues. However, many data sources lack this information. We aimed to estimate duration of individual prescriptions for oral glucocorticoids and to describe continuous treatment episodes using the parametric waiting time distribution. METHODS: We used Danish nationwide registries to identify all prescriptions for oral glucocorticoids during 1996–2014. We applied the parametric waiting time distribution to estimate duration of individual prescriptions each year by estimating the 80th, 90th, 95th and 99th percentiles for the interarrival distribution. These corresponded to the time since last prescription during which 80%, 90%, 95% and 99% of users presented a new prescription for redemption. We used the Kaplan–Meier survival function to estimate length of first continuous treatment episodes by assigning estimated prescription duration to each prescription and thereby create treatment episodes from overlapping prescriptions. RESULTS: We identified 5,691,985 prescriptions issued to 854,429 individuals of whom 351,202 (41%) only redeemed 1 prescription in the whole study period. The 80th percentile for prescription duration ranged from 87 to 120 days, the 90th percentile from 116 to 150 days, the 95th percentile from 147 to 181 days, and the 99th percentile from 228 to 259 days during 1996–2014. Based on the 80th, 90th, 95th and 99th percentiles of prescription duration, the median length of continuous treatment was 113, 141, 170 and 243 days, respectively. CONCLUSION: Our method and results may provide an important framework for future pharmacoepidemiological studies. The choice of which percentile of the interarrival distribution to apply as prescription duration has an impact on the level of misclassification. Use of the 80th percentile provides a measure of drug exposure that is specific, while the 99th percentile provides a sensitive measure. Dove Medical Press 2017-11-16 /pmc/articles/PMC5697451/ /pubmed/29180903 http://dx.doi.org/10.2147/CLEP.S148671 Text en © 2017 Laugesen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Laugesen, Kristina Støvring, Henrik Hallas, Jesper Pottegård, Anton Jørgensen, Jens Otto Lunde Sørensen, Henrik Toft Petersen, Irene Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title | Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title_full | Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title_fullStr | Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title_full_unstemmed | Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title_short | Prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
title_sort | prescription duration and treatment episodes in oral glucocorticoid users: application of the parametric waiting time distribution |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697451/ https://www.ncbi.nlm.nih.gov/pubmed/29180903 http://dx.doi.org/10.2147/CLEP.S148671 |
work_keys_str_mv | AT laugesenkristina prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT støvringhenrik prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT hallasjesper prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT pottegardanton prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT jørgensenjensottolunde prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT sørensenhenriktoft prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution AT petersenirene prescriptiondurationandtreatmentepisodesinoralglucocorticoidusersapplicationoftheparametricwaitingtimedistribution |